IN2014DN10408A - - Google Patents

Info

Publication number
IN2014DN10408A
IN2014DN10408A IN10408DEN2014A IN2014DN10408A IN 2014DN10408 A IN2014DN10408 A IN 2014DN10408A IN 10408DEN2014 A IN10408DEN2014 A IN 10408DEN2014A IN 2014DN10408 A IN2014DN10408 A IN 2014DN10408A
Authority
IN
India
Prior art keywords
methods
antigen
increasing
immune cells
specific
Prior art date
Application number
Other languages
English (en)
Inventor
Ronald James Jackson
Charani Ranasinghe
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902345A external-priority patent/AU2012902345A0/en
Application filed by Univ Australian filed Critical Univ Australian
Publication of IN2014DN10408A publication Critical patent/IN2014DN10408A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IN10408DEN2014 2012-06-05 2013-06-05 IN2014DN10408A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902345A AU2012902345A0 (en) 2012-06-05 Vaccination with Interleukin-4 Antagonists
PCT/AU2013/000589 WO2013181696A1 (fr) 2012-06-05 2013-06-05 Vaccination avec des antagonistes de l'interleukine-4

Publications (1)

Publication Number Publication Date
IN2014DN10408A true IN2014DN10408A (fr) 2015-08-14

Family

ID=49711200

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10408DEN2014 IN2014DN10408A (fr) 2012-06-05 2013-06-05

Country Status (15)

Country Link
US (1) US20150150963A1 (fr)
EP (2) EP3530283A1 (fr)
JP (1) JP2015520175A (fr)
KR (1) KR20150021088A (fr)
CN (1) CN104717971A (fr)
AU (1) AU2013271338B2 (fr)
BR (1) BR112014030436A2 (fr)
CA (1) CA2875683A1 (fr)
HK (1) HK1203358A1 (fr)
IL (1) IL236092A0 (fr)
IN (1) IN2014DN10408A (fr)
NZ (1) NZ702721A (fr)
SG (1) SG11201408101TA (fr)
WO (1) WO2013181696A1 (fr)
ZA (1) ZA201409076B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505554A (ja) * 2016-02-19 2019-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3282188B2 (ja) 1991-06-27 2002-05-13 日本電気株式会社 半導体メモリ装置
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP1512693B1 (fr) 1993-03-31 2008-11-19 Nippon Zeon Co., Ltd. Nouveau polypeptide, ADN codant pour le dit polypeptide, vecteur de recombinaison contenant ledite ADN, virus de recombinaison préparé en utilisant ledit vecteur et son utilistation
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CN1112943C (zh) 1994-01-21 2003-07-02 粉剂注射疫苗股份有限公司 气体驱动的基因送递装置
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US6265387B1 (en) 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP1042494A1 (fr) 1997-12-23 2000-10-11 Introgene B.V. Virus de recombinaison chimeriques faits d'un adenovirus et d'un virus adeno-associe utiles pour l'integration d'informations genetiques etrangeres dans l'adn chromosomique de cellules cibles
US6972013B1 (en) 1998-07-13 2005-12-06 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7608273B2 (en) 1998-08-12 2009-10-27 University Of Western Ontario Recombinant lentivirus encoding modified GP 120 signal sequences
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
EP1849873B1 (fr) 1999-04-29 2011-10-12 Gbp Ip, Llc Procédé et supports de production de vecteurs de lentivirus recombinant sécurisé à fort dosage
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
WO2001083797A2 (fr) 2000-04-28 2001-11-08 Avigen, Inc. Polynucleotides utilises dans la production de virions de virus recombinants associes aux adenovirus
EA007811B1 (ru) 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
WO2004028563A1 (fr) 2002-09-27 2004-04-08 Genexine Inc. Vaccin ameliorant l'immunite protectrice vis-a-vis du virus de l'hepatite c au moyen d'adn plasmidique et d'adenovirus recombinant
WO2007121194A1 (fr) * 2006-04-10 2007-10-25 The Regents Of The University Of California Compositions immunogènes à agents pathogènes intracellulaires recombinés immunostimulants, et procédés d'utilisation
WO2006012221A2 (fr) 2004-06-25 2006-02-02 The Regents Of The University Of California Arnsi specifique de cellules cibles et ses procedes d'utilisation
WO2006135436A2 (fr) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition de l'expression genique et ses usages therapeutiques
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8048404B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
US7611690B2 (en) 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
CA2635996A1 (fr) * 2006-01-11 2007-07-19 Aerovance, Inc. Procedes et compositions pour le traitement de l'asthme chez les primates humains et non humains
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
WO2010120511A2 (fr) * 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Procédé de traitement de troubles respiratoires
WO2011003138A1 (fr) * 2009-07-06 2011-01-13 The Australian National University Compositions immunorégulatrices comportant des inhibiteurs de l'interleukine 13 et leurs utilisations

Also Published As

Publication number Publication date
EP2854837A1 (fr) 2015-04-08
SG11201408101TA (en) 2015-01-29
CN104717971A (zh) 2015-06-17
NZ702721A (en) 2016-11-25
AU2013271338A1 (en) 2015-01-15
KR20150021088A (ko) 2015-02-27
IL236092A0 (en) 2015-01-29
JP2015520175A (ja) 2015-07-16
EP2854837A4 (fr) 2016-06-29
EP3530283A1 (fr) 2019-08-28
BR112014030436A2 (pt) 2017-09-26
CA2875683A1 (fr) 2013-12-12
WO2013181696A1 (fr) 2013-12-12
AU2013271338B2 (en) 2018-05-24
ZA201409076B (en) 2017-06-28
US20150150963A1 (en) 2015-06-04
HK1203358A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2018009990A (es) Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
GB2540694A (en) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PH12018501047A1 (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
EA201890782A1 (ru) Способ перенацеливания t-клеток для лечения инфекции hiv
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
WO2013070776A8 (fr) Anticorps neutralisant la gp41 et leur utilisation
WO2007144720A3 (fr) Produits pharmaceutiques
WO2012047267A3 (fr) Immunogène polyvalent
WO2011103417A3 (fr) Vecteurs exprimant des antigènes du vih et le gm-csf et procédés associés destinés à générer une réponse immunitaire
EA201290956A1 (ru) Вакцина против вич
WO2012145238A3 (fr) Procédés pour réduire une réponse immunitaire indésirable à un antigène étranger chez un sujet humain avec des anticorps anti-cd4 ou des fragments de ceux-ci se liant aux cd4 ou des molécules se liant aux cd4
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
IN2014KN02740A (fr)
WO2014160747A3 (fr) Compositions et méthodes de traitement ou de prévention d'une infection par le virus de l'immunodéficience humaine
IN2014DN10408A (fr)
AU2013235442A8 (en) Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate
WO2014040025A3 (fr) Immunogènes d'anticorps de vih-1 largement neutralisants, procédés de génération et utilisations associés
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
AP2012006258A0 (en) Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
WO2015048796A3 (fr) Polypeptides immunogènes mosaïques de l'enveloppe du vih